Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Current Assets (2024 - 2025)

Evommune (EVMN) has disclosed Current Assets for 2 consecutive years, with $153.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 107.44% to $153.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $153.5 million, a 107.44% increase, with the full-year FY2025 number at $153.5 million, up 107.44% from a year prior.
  • Current Assets was $153.5 million for Q4 2025 at Evommune, up from $81.9 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $153.5 million in Q4 2025 to a low of $74.0 million in Q4 2024.